Gamelin Erick 4

What Happened

• Erick Gamelin, Chief Development Officer of Acrivon Therapeutics (ACRV), had 404 shares withheld by the issuer to satisfy mandatory tax withholding upon the vesting of restricted stock units.
• The withholding occurred on 2026-05-14 at $1.92 per share, resulting in a disposition value of $776. This is a tax-withholding event (routine), not an open-market sale or purchase.

Key Details

• Transaction date: 2026-05-14; Form 4 filed: 2026-05-18 (timely filed).
• Shares withheld/disposed: 404 at $1.92 per share; aggregate value reported: $776.
• Shares owned after transaction: Not specified in the provided filing summary.
• Footnote: F1 — "Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units."
• Transaction code: F (tax withholding).

Context

• This was a cashless withholding to cover taxes on vested RSUs, a routine administrative transaction that does not necessarily indicate a change in the insider’s view of the company.
• Such withholdings are common and differ from open-market sales (which can signal liquidity needs) or purchases (which some investors view as bullish).